- Advancements in CMT1A and CMT1B Research Highlight CMTA’s Impact
Exciting news from a CMTA-STAR-funded research project has been published by Jordan VerPlank, PhD, Assistant Professor in the Department of Anatomy, Physiology, and Genetics at the Uniformed Services University of the Health Sciences (USU). The ...
Read more ... - CMTA Partners with Actio Bio on CMT2C Focus Group
The Charcot-Marie-Tooth Association (CMTA), in collaboration with Actio Biosciences (Actio Bio), hosted a virtual patient focus group for individuals diagnosed with Charcot-Marie-Tooth disease Type 2C (CMT2C), also known as TRPV4 Neuropathy.
Engaging volunteer experts from ...
Read more ... - CMT2F Natural History Study Nears Full Recruitment as Biomarker Analysis Begins
With CMTA support of $302,071, an international team of researchers from the Inherited Neuropathies Consortium, led by Micheal Shy, MD, at the University of Iowa in Iowa City, IA, is studying the natural history of ...
Read more ... - Recap: 2024 CMTA Patient & Research Summit
Help for Today and Hope for Tomorrow: Empowering the CMT Community at the 2024 CMTA Patient & Research Summit in Denver
The 2024 CMTA Patient & Research Summit in Colorado was a remarkable gathering of more ...
Read more ... - CMTA’s CRISPR Research Initiative Advances for CMT1A and CMT1B
The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research that impacts the lives of those living with Charcot-Marie-Tooth disease (CMT) and is excited to share progress in a CRISPR research project focused on developing ...
Read more ...